Literature DB >> 28070839

1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes.

Francesco Secchi1, Giovanni Di Leo1, Marcello Petrini2, Riccardo Spairani2, Marco Alì3, Marco Guazzi4, Francesco Sardanelli1,5.   

Abstract

PURPOSE: The clinical differentiation between athlete's heart and mild forms of non-obstructive hypertrophic cardiomyopathy (HCM) is crucial. We hypothesized that differences do exist between the myocardial metabolism of patients with non-obstructive HCM and competitive athletes (CAs). Our aim was to evaluate myocardial metabolism with 31P-MRS and 1H-MRS in HCM patients and CAs.
MATERIALS AND METHODS: After Ethics Committee approval, 15 CAs and 7 HCM patients were prospectively enrolled. They underwent a 1.5-T cardiac MR including electrocardiographically triggered cine images, single-voxel 1H-MRS and multivoxel 31P-MRS. 1H-MRS was performed after imaging using standard coil with the patient in the supine position; thereafter, 31P-MRS was performed using a dedicated coil, in the prone position. Data were reported as median and interquartile range. Mann-Whitney U test was used.
RESULTS: In CAs, left ventricular mass index was 72 (66-83) g/m2, septal thickness 10 (10-11) mm, end diastolic volume index 95 (85-102) ml/m2, end systolic volume index 30 (28-32) ml/m2 and ejection fraction 68% (65-69%); in HCM patients, 81 (76-111) g/m2 (P = 0.052), 18 (15-21) mm (P = 0.003), 73 (58-76) ml/m2 (P = 0.029), 20 (16-34) ml/m2 (P = 0.274) and 68% (55-73%) (P = 1.000), respectively. At 1H-MRS, total lipids were 35 (0-183) arbitrary units (au) for CA and 763 (155-1994) au for HCM patients (P = 0.046). At 31P-MRS, PCr/γATP was 5 (4-6) au for CA and 4 (2-5) au for HCM patients (P = 0.230). Examination time was 20 min for imaging only, 5 min for 1H-MRS and 15 min for 31P-MRS.
CONCLUSIONS: We observed a significant increase of myocardial lipids, but a preserved PCr/γATP ratio in the metabolism of HCM patients compared with competitive CAs.

Entities:  

Keywords:  Athlete’s heart; Hypertrophic cardiomyopathy; Magnetic resonance spectroscopy; Myocardial metabolism

Mesh:

Substances:

Year:  2017        PMID: 28070839     DOI: 10.1007/s11547-016-0718-2

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  40 in total

Review 1.  Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy.

Authors:  E D Wigle
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 2.  Clinical cardiac magnetic resonance spectroscopy.

Authors:  Cameron J Holloway; Joseph Suttie; Sairia Dass; Stefan Neubauer
Journal:  Prog Cardiovasc Dis       Date:  2011 Nov-Dec       Impact factor: 8.194

3.  Sarcomeric genotyping in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

4.  Penetrance of familial hypertrophic cardiomyopathy.

Authors:  P Charron; L Carrier; O Dubourg; F Tesson; M Desnos; P Richard; G Bonne; P Guicheney; B Hainque; J B Bouhour; A Mallet; J Feingold; K Schwartz; M Komajda
Journal:  Genet Couns       Date:  1997

5.  Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging.

Authors:  A Hansch; R Rzanny; J-P Heyne; U Leder; J R Reichenbach; W A Kaiser
Journal:  Eur Radiol       Date:  2005-01-04       Impact factor: 5.315

6.  Observation of cardiac lipids in humans by localized 1H magnetic resonance spectroscopic imaging.

Authors:  J A den Hollander; W T Evanochko; G M Pohost
Journal:  Magn Reson Med       Date:  1994-08       Impact factor: 4.668

Review 7.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

Review 8.  Sudden cardiac death and the 'athlete's heart'.

Authors:  J N Wight; D Salem
Journal:  Arch Intern Med       Date:  1995-07-24

9.  The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes.

Authors:  A Pelliccia; B J Maron; A Spataro; M A Proschan; P Spirito
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  3 in total

1.  Myocardial triglycerides in cardiac amyloidosis assessed by proton cardiovascular magnetic resonance spectroscopy.

Authors:  Mareike Gastl; Sophie M Peereboom; Alexander Gotschy; Maximilian Fuetterer; Constantin von Deuster; Florian Boenner; Malte Kelm; Rahel Schwotzer; Andreas J Flammer; Robert Manka; Sebastian Kozerke
Journal:  J Cardiovasc Magn Reson       Date:  2019-01-31       Impact factor: 5.364

2.  Heart of the World's Top Ultramarathon Runner-Not Necessarily Much Different from Normal.

Authors:  Robert Gajda; Anna Klisiewicz; Vadym Matsibora; Dorota Piotrowska-Kownacka; Elżbieta Katarzyna Biernacka
Journal:  Diagnostics (Basel)       Date:  2020-01-28

Review 3.  In Vivo Magnetic Resonance Spectroscopy Methods for Investigating Cardiac Metabolism.

Authors:  Morteza Esmaeili; Riyas Vettukattil
Journal:  Metabolites       Date:  2022-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.